Erik Olsson
Doktorand vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Henrik Lindman
- E-post:
- erikjohan.olsson@igp.uu.se
- Besöksadress:
- Akademiska sjukhuset, ing 100/101, plan 1
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ing 100/101
751 85 Uppsala
Publikationer
Senaste publikationer
-
Ingår i Clinical and Translational Radiation Oncology, 2027
- DOI för PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
- Ladda ner fulltext (pdf) av PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
-
Ingår i The Breast, 2025
- DOI för Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
- Ladda ner fulltext (pdf) av Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
-
Ingår i The Breast, 2025
-
Ingår i ESMO Real World Data and Digital Oncology, 2024
- DOI för Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
- Ladda ner fulltext (pdf) av Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
Alla publikationer
Artiklar i tidskrift
-
Ingår i Clinical and Translational Radiation Oncology, 2027
- DOI för PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
- Ladda ner fulltext (pdf) av PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
-
Ingår i The Breast, 2025
- DOI för Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
- Ladda ner fulltext (pdf) av Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
-
Ingår i The Breast, 2025
-
Ingår i ESMO Real World Data and Digital Oncology, 2024
- DOI för Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
- Ladda ner fulltext (pdf) av Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study